Loading...
OTCM
LOBEF
Market cap5mUSD
Dec 05, Last price  
0.03USD
1D
-2.00%
1Q
-21.60%
IPO
-63.25%
Name

Lobe Sciences Ltd

Chart & Performance

D1W1MN
OTCM:LOBEF chart
P/E
P/S
57.61
EPS
Div Yield, %
Shrs. gr., 5y
72.62%
Rev. gr., 5y
-29.35%
Revenues
136k
-83.80%
0000000773,792884,83700840,534136,205
Net income
-4m
L-6.08%
-91,001-93,104-133,955-106,424-170,839-55,972-51,795-754,431-3,436,073-9,658,412-12,252,852-4,707,349-4,421,000
CFO
-462k
L-73.10%
-44,924-84,704-126,342-106,202-59,767-44,843-51,934-2,043,609-1,222,417-5,037,358-2,730,729-1,718,644-462,293

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
IPO date
Jun 19, 2012
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑082023‑082022‑082021‑082020‑082019‑082017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT